The Impact of Thromboprophylaxis on Progression Free Survival of Patients With Advanced Pancreatic Cancer

Summary

This is a prospective, randomized, multicenter, open-label, blinded-endpoint Phase III clinical trial to investigate the impact of thromboprophylaxis using innohep, beyond anticoagulation in the improvement of the clinical outcomes in active pancreatic cancer patients receiving systemic anti-neoplasmatic treatment. The number of patients that will be enrolled is 450. The enrollment period is 24 months and the follow up period is 10 months.

Timeline

Start

2022-02-10

Primary completion

2024-12-31

Completion

2024-12-31

Drugs

Indications